Amoy Diagnostics Co

Amoy Diagnostics Co EBIT per Employee

The EBIT per Employee of Amoy Diagnostics Co (300685.SZ) as of Oct 30, 2026 is 379,343.69 CNY. In the previous year, EBIT per Employee was 266,101.73 CNY — a change of 42.56% (higher).

EBIT per Employee

379,343.69CNY

YoY

42.56%

Last updated:

EBIT per Employee of Amoy Diagnostics Co is 2025 379,343.69 CNY. EBIT per Employee of Amoy Diagnostics Co was 2024 266,101.73 CNY. It decreases by 42.56% higher compared to the previous year.

The Amoy Diagnostics Co EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
130,721.62 CNY
Jan 1, 2019
147,547.80 CNY
Jan 1, 2020
183,601.69 CNY
Jan 1, 2021
230,007.57 CNY
Jan 1, 2022
261,273.96 CNY
Jan 1, 2023
273,611.90 CNY
Jan 1, 2024
266,101.73 CNY
Jan 1, 2025
379,343.69 CNY
The Amoy Diagnostics Co EBIT per Employee history
YEAREBIT per EmployeeYoY
379,343.69CNY+42.56%
266,101.73CNY-2.74%
273,611.90CNY+4.72%
261,273.96CNY+13.59%
230,007.57CNY+25.28%
183,601.69CNY+24.44%
147,547.80CNY+12.87%
130,721.62CNY+35.33%
96,598.05CNY+70.86%
56,537.28CNY+222.36%
17,538.68CNY+14.23%
15,353.47CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

EBIT per Employee of Amoy Diagnostics Co is 379,343.69 CNY in 2025.

EBIT per Employee of Amoy Diagnostics Co changed from 266,101.73 CNY to 379,343.69 CNY, representing a 42.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Amoy Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co